Moderna has appointed Juan Andres as Chief Operating Officer, effective 5 October 2026, as the company expands its operations into oncology. Andres previously worked at Moderna from 2017 to 2023, leading the build-out of its manufacturing capabilities during the COVID-19 vaccine scale-up. The new role supports Moderna's preparation for the potential launch of intismeran autogene following positive Phase 3 results and the advancement of its broader oncology portfolio. The company's infectious disease franchise now includes five approved vaccines, following recent US FDA approval of its seasonal flu vaccine and European Commission authorisation of its flu-COVID combination vaccine. Jerh Collins, Chief Technical Operations and Quality Officer, will retire after four years with the company. Andres will oversee manufacturing operations and work across the organisation to drive execution of Moderna's strategy.

Moderna eyes cancer vaccine filing as it expands beyond COVID. Moderna (NASDAQ:MRNA) executives emphasized the company's evolution beyond COVID-19 vaccines during a discussion with Bernstein, highlighting its mRNA platform, personalized cancer vaccine program intismeran, rare-disease pipeline and plans to expand therapeutics development. Chief Executive Officer Stéphane Bancel said Moderna has been an mRNA platform company since its founding and described the COVID-19 vaccine as an unplanned but necessary response to the pandemic rather than the company's long-term strategy. He said Moderna currently has a vaccine business with five approved products and two product launches planned this year, alongside oncology, rare disease and autoimmune programs. Discover more Access Premium News Track Market Trends Investing Newsletters Bancel said the company believes it is now the only remaining broad mRNA platform company following changes among competitors, including CureVac's failed late-stage COVID vaccine, Sanofi's decision to stop mRNA vaccine programs following its acquisition of Translate Bio, and BioNTech's announced organizational changes. Intismeran moves toward regulatory filing. Much of the discussion focused on intismeran, Moderna's individualized mRNA cancer vaccine being developed with Merck. Chief Development Officer David Berman said the Phase 3 melanoma study met both its primary endpoint and a secondary endpoint of distant metastasis-free survival at the first interim analysis. Berman characterized the study as a rigorously controlled, blinded trial involving approximately 1,100 patients that compared intismeran plus Keytruda with Keytruda alone. He said the company believes the results provide a strong case for regulatory approval, though Moderna plans to focus first on filing its biologics license application. The executives said the program could extend into other cancer settings. Berman cited ongoing studies in lung cancer, renal cell carcinoma, bladder cancer, pancreatic cancer and gastric cancer. Moderna has three Phase 3 lung cancer trials, including an adjuvant trial where it expects randomization to be completed later this year, according to Berman. Berman said Moderna is also studying intismeran in earlier stages of disease, including a Phase 3 trial in stage 1 lung cancer and a randomized Phase 2 trial in non-muscle-invasive bladder cancer. He said the company's view is that the treatment may be active without a PD-1 inhibitor, potentially creating opportunities in settings where checkpoint inhibitors are not commonly used. Manufacturing and commercial preparation. Bancel said Moderna owns the proprietary work involved in selecting the 34 mutations included in each individualized cancer vaccine. External partners provide DNA sequencing data from healthy and cancer cells, while Moderna conducts the downstream analysis and selection process, he said. He described intismeran manufacturing as a synthetic, cell-free liquid process that can be scaled through smaller equipment footprints and faster cycle times. Bancel said the principal bottleneck may be hospital operations rather than manufacturing, particularly the ability to rapidly obtain biopsies and related patient information. Moderna and Merck are establishing teams to support hospitals and standardize those processes, according to Bancel. He said the companies have built a digital platform to track operational steps while maintaining patient privacy. Under the collaboration, Moderna and Merck share costs equally, including commercial, clinical, manufacturing and capital expenditures, with remaining profit split evenly between the companies, Bancel said. He declined to discuss potential pricing before additional clinical data are presented. Broader oncology and rare-disease programs. Berman also outlined Moderna's efforts to develop off-the-shelf cancer vaccines. The company has a Phase 1/2 program in the United Kingdom for people with Lynch syndrome, an inherited condition associated with increased cancer risk. The long-term goal is cancer prevention, he said. Other early oncology efforts include shared-antigen cancer vaccines and a Phase 1 multiple myeloma program that uses three T-cell engagers in a single treatment. Berman said the company expects to share data from the multiple myeloma study later this year. Moderna is also advancing an in vivo CAR-T program and other autoimmune disease programs. In rare disease, Bancel said the company expects pivotal data for propionic acidemia by year-end. He described the program as the first of what Moderna expects could become a broader liver-focused rare-disease franchise, using mRNA to direct the liver to produce missing or deficient proteins. Bancel said Moderna has published work involving more than 12 rare genetic liver-disease models and intends to advance additional programs using the same lipid delivery approach and manufacturing infrastructure as its propionic acidemia candidate. Long-Term platform strategy. Bancel said Moderna recently raised $2.6 billion through convertible notes and remains focused on long-term platform development rather than near-term earnings. He said the company's sales declined sharply after the pandemic and that it restructured while continuing to invest in its pipeline. Looking ahead, Bancel pointed to artificial intelligence as a potential accelerator for mRNA drug development, citing Moderna's rapid design of its COVID-19 vaccine candidate after the viral sequence became available. He said the company's platform could allow it to respond rapidly to new biological discoveries across vaccines, oncology, autoimmune disease and rare diseases. About Moderna (NASDAQ:MRNA). Moderna, Inc is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions. The company's commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases. Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements.

Compliance Jobs Report: sept. 25. By Matt Kelly | September 25, 2026 The Compliance Jobs Report rolls onward this week with new hires at Dollar General, BitGo, Moderna, Coupang, NCR, and more. Radical Compliance also have promotions at Citibank, Electrolux, and elsewhere; some gossip about a senior compliance role at Genentech; and job leads in financial services, oil, and food. Plus Meme of the Week! Radical Compliance gather the Jobs Report news items from LinkedIn, press releases, and wherever else Radical Compliance can find tips - and thank you to everyone who sends them in, you make the Jobs Report possible! If you have any gossip to share (even confidentially) email me at [email protected] or find me on LinkedIn. Compliance Jobs. First, cryptocurrency platform BitGo has named Alex Rozman chief compliance officer. Rozman comes to the company from Exodus, a cold wallet crypto storage business, where he had been chief compliance officer since 2024. He succeeds Jeff Horowitz, who retired from BitGo in June. Alisha Cieslak has been hired as chief compliance officer at Dollar General. Cieslak comes to the discount retailer after 12 years at Gordon Food Service in Michigan, where she had been chief legal and risk officer since 2017. Devin Smith has been hired at Moderna as chief ethics and compliance officer and head of legal. Smith comes to the pioneering vaccine company from IO Biotech, where he had been general counsel and chief compliance officer until earlier this summer. In South Korea, e-commerce giant Coupang Fulfillment Services has hired Mukul Chadha as senior director of compliance. Chadha comes to Coupang from PhonePe, where he had been director of ethics and anti-corruption for six years. Flex, a private bank and fintech based in San Francisco, has hired Elina Shulman as deputy chief compliance officer. Shulman rolls into Flex from Emigrant Bank, where she had also been deputy chief compliance officer since 2021. Christine Streeter has joined Ionis Pharmaceuticals as senior manager of healthcare compliance operations. Streeter was last seen at Takeda, where she had been a business operations manager until June. NCR Voyix, the business that started as National Cash Register Co. in the 1800s and now bills itself as a payments software business, has hired Anna Grover as senior executive director for compliance. Grover comes to NCR after eight years at Assurant, where she most recently was global compliance counsel. Were you one of the many who applied for Genentech's chief healthcare compliance officer role that the pharma giant advertised earlier this summer? Radical Compliance is reliably told Genentech has begun informing applicants that "we have now completed recruitment activities." Presumably that means a compliance officer out there either has the job or is about to get it, and we'll all see an "I'm happy to announce..." update on LinkedIn soon after. Lauren Smith just landed at Signature Aviation, where she will be senior associate general counsel for ethics, data, and employment. Smith comes to Signature from personnel company AlphaStaffHCM, where she had been general counsel since 2024. Jodi Faustin has been hired at WellMed Optum Florida, a healthcare system in Tampa, Fla., as director of compliance and privacy. Faustin previously worked as associate director of compliance for CareSource until earlier this spring. In Canada, Danielle Reid is joining marine transportation business Sea Centric Inc. as training and compliance manager, working from St. John's, Newfoundland. (Also the setting for "Son of a Critch," if you're ever looking for a family-friendly sitcom.) Reid comes to Sea Centric from Parker Wellbore, where she had been global senior training lead since 2020. Custom Health, a healthcare tech firm based in British Columbia, has hired Christina Garcia as chief compliance and regulatory officer. Garcia joins Custom from SAGA Diagnostics, where she had been vice president of compliance. Peapack Private Bank & Trust has tapped Kevin Bertscha as chief audit executive. Bertscha previously worked at Oppenheimer & Co. as managing director for internal audit. Eddie Dial has been hired at insurance carrier Globe Life as a compliance analyst. Dial joins Globe Life after 29 years at Teleperformance, where he most recently had been senior manager of regulatory compliance and quality assurance. Emerus Holdings, an operator of neighborhood hospitals around the United States, has tapped Deena Ombres as vice president of compliance and risk. Ombres joins Emerus from United Musculoskeletal Partners, where she had been chief compliance officer since 2023. Wilzy, a rather delightfully named wealth management business based in Egypt, has named Ahmed Ebrahim head of compliance. Ebrahim previously worked at Mubasher Capital Holding in Egypt as compliance and anti-money laundering officer. IQ-EQ, an investor services group based in Luxembourg, has hired Cid von der Goltz Ferreira as head of anti-money laundering compliance. Ferreira comes to IQ-EQ from HACA Partners, where he had been senior compliance officer. CapPru, a real estate investment firm in Australia, has named Greg Thomas head of compliance. Thomas comes to the firm after two years at the Australia offices of PIMCO, where he had been vice president and senior compliance officer. AKÖde, an online payments business in Turkey affiliated with regional banking giant Akbank, has named Cengiz Akyuz head of compliance and anti-money laundering. Akyuz joins the firm after five years at VodaFone's Turkey operations, where he most recently had been compliance manager. And Habiba Khatun has a new job as Medicaid compliance specialist for Adobe Care in New York. She previously worked as a social work intern for the Center for Alternative Sentencing and Employment Services. Welcome to the profession, Ms. Khatun. Moving up the ladder. Intriguing promotion at Citibank, where Sharad Joshi has moved up from managing director for infrastructure controls and technology risk to chief auditor for artificial intelligence assurance. A sign of its AI times... Electrolux just promoted Vagner Casagrande from Latin America compliance specialist to Latin America compliance lead. He is based in Brazil. Professional services firm WSP has promoted Avni Parikh from vice president for ethics and compliance to senior vice president of the same. Bonita Stone has been promoted at MVB Bank, from bank operations senior manager to director of enterprise operations risk and controls. Walmart Canada has promoted Antonella Mercurio, from market lead for anti-corruption compliance monitoring to head of ethics and compliance continuous improvement for testing and monitoring. Johnson & Johnson has promoted Maria Mamoni in its Greece operations, from healthcare compliance lead specialist to senior specialist. And you gotta love a promotion like this! Elin Cherry has moved up at Copper (some blockchain infrastructure payments business) from chief compliance officer to co-CEO! That's one way to set a strong tone at the top. Vendors & Service providers. Lucia Wind just blew into FloQast, maker of corporate accounting software, as senior vice president of the risk and audit advisory practice. Wind had previously been executive director at COSO since 2023 until this summer, when she moved into a part-time role as COSO chair for the rest of 2026. COSO is recruiting a new permanent chair to start next year. Open req orders. Agribusiness giant Cargill is hiring an anti-bribery and anti-fraud program leader. Job is based in suburban Minneapolis (Wayzata, Minn., to be precise) with a salary range of $165,000 to $200,000. John Hancock is seeking a global chief compliance officer for its Manulife investment business, which focuses on timberland, agriculture, and other private equity investments. Job is based in Boston, with a preposterously wide salary range of $153,000 to $283,000. ConocoPhillips is staffing up its trade compliance team and has three roles it's trying to fill: a trade compliance analyst role; a senior adviser on trade compliance; and a senior counsel on import and trade compliance. All jobs are based in Houston, and none of them include a salary range because Texas. Compliance Meme of the Week. That's all for this week's report. As always, if you have a tip or want to brag about your new job, promotion, career milestone, or anything else, email me at [email protected] or find me on LinkedIn. I'm always happy to give credit to the many hard-working people here in its corner of the business universe.